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PURPOSE. We investigated the therapeutic effect of nontoxic concentrations of tanshinone IIA
(TanIIA) from Salvia miltiorrhiza in primary cultures of orbital fibroblasts from Graves’
orbitopathy (GO).
METHODS. The effect of TanIIA on IL-1b–induced proinflammatory cytokine (IL-6, IL-8, MCP-1)
expression was determined by real-time PCR. Antioxidant activity was investigated by
measuring intracellular reactive oxygen species (ROS) generation stimulated by cigarette
smoke extract (CSE) and heme oxygenase-1 (HO-1) expression. To evaluate antiadipogenic
activity, fibroblasts were subjected to a differentiation protocol, including peroxisome
proliferator activator gamma (PPARc) agonist, for 10 days, and exposed to TanIIA during
adipocyte differentiation. Differentiated cells were stained with Oil Red O, and the expression
of adipogenesis-related factors, PPARc, and CCAAT-enhancer-binding proteins (C/EBP) a and b
were determined by Western blot.
RESULTS. Expression of IL-6, IL-8, and MCP-1 mRNA was inhibited by TanIIA pretreatment
in a dose-dependent manner in GO orbital fibroblasts (P < 0.05). Tanshinone IIA
decreased CSE- or H2O2-induced ROS levels in a dose-dependent manner and upregulated
HO-1 protein expression in a time- and dose-dependent manner (P < 0.001). Treatment of
orbital fibroblasts with TanIIA increased phosphorylated extracellular signal-regulated
kinase (pERK), and an ERK inhibitor significantly blocked TanIIA-induced HO-1
upregulation. Adipogenesis was inhibited by TanIIA in a dose-dependent manner (P <
0.001), as evidenced by Oil Red O stain and decreased PPARc and C/EBPa expression in
Western blot analysis.
CONCLUSIONS. Our study results suggest that TanIIA possesses significant anti-inflammatory,
antioxidant, and antiadipogenic effects in primary orbital fibroblasts. These results provide
the basis for further study of the potential use of TanIIA to treat GO. Tanshinone IIA showed
significant anti-inflammatory, antioxidant, and antiadipogenic effects in primary orbital
fibroblasts from Graves’ orbitopathy patients. These results provide the basis for further study
of the potential use of tanshinone IIA to treat Graves’ orbitopathy.
Key words: adipogenesis, Graves’ orbitopathy, heme oxygenase-1, inflammation, orbital
fibroblasts, oxidative stress, tanshinone IIA
Graves’ disease is an autoimmune disease of the thyroidgland in which autoantibodies bind to the thyrotropin
receptor on thyroid follicular cells, thereby activating gland
function and leading to excess production of thyroid hor-
mones.1 Up to 50% of patients with Graves’ disease develop
pathological manifestations in the eye, known as Graves’
orbitopathy (GO).2 Enlargement of extraocular muscle bodies
together with an increase in orbital connective/fatty tissue
within the bony orbits is responsible for most of the orbital
complications in patients with moderate to severe GO.3 In
addition, an overabundance of adipose tissue within the orbits
is another prominent feature of GO. It is likely that orbital
adipose tissue in GO is more cellular and comprises a higher
proportion of preadipocytes capable of differentiating into
adipocytes.4 The process of adipocyte differentiation appears
to be a phenotypic attribute of orbital fibroblasts that is not
observed in dermal and perimysial fibroblasts. The mechanistic
connections between the pathogenic components in GO are
poorly understood.
Oxidative stress has also been implicated in the pathogen-
esis of GO, and cigarette smoking is known to be one of the
major environmental factors affecting GO.5 Cigarette smoke is
considered to act, in part, by enhancing the generation of
reactive oxygen species (ROS) and increasing oxidative stress in
the closed bony orbital environment, either through direct
contact with the sinus and medial wall, or indirectly through
the bloodstream.5 However, the contribution of ROS to the
pathogenesis of GO is unclear.
There is no completely reliable, specific, and safe medical
therapeutic agents for moderate to severe GO. Glucocorticoids
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are indicated as the first-line treatment due to their anti-
inflammatory and immunosuppressive actions, alone or in
combination with orbital radiotherapy.6 However, the manage-
ment of moderate to severe GO is challenging, and often not
satisfactory. Previous treatments, such as high-dose glucocor-
ticoids and/or orbital radiotherapy, are mostly effective in
patients with severe and active eye disease.7 Soft tissue
inflammatory changes, recent-onset extraocular muscle in-
volvement, and optic neuropathy are the most responsive to
glucocorticosteroids, whereas proptosis and long-standing
extraocular muscle involvement associated with fibrotic
changes are poorly influenced. Adverse effects and complica-
tions caused by systemic glucocorticoid therapy also should
not be ignored.
Tanshinone, isolated from Salvia miltiorrhiza bunge
(danshen), has been widely used to treat coronary, cerebro-
vascular, and cardiovascular disease in traditional Chinese
medicine. Owing to its purported biological activity and lack of
serious side effects, as confirmed by pharmacological investi-
gations and clinical use, a number of traditional Chinese
medicinal preparations have been developed containing
danshen.8 Tanshinone IIA (TanIIA), a lipophilic diterpene, is
the most abundant active ingredient and is structurally
representative of tanshinone.9 It is available as a purified
sulfonate salt for use in stroke, heart attack, and angina
patients,10,11 and can reduce the brain infarct volume in
transient focal cerebral ischemia in mice. It is suggested that
the therapeutic effect of TanIIA on atherosclerosis may result
from its antioxidant and anti-inflammatory properties.12,13
Tanshinone IIA is also reported to have antifibrotic14 and
antiadipogenetic15,16 effects.
Tanshinone IIA has recently been found to inhibit 3T3-L1
preadipocyte differentiation and transcriptional activity in full-
length peroxisome proliferator activator gamma (PPARc) and
PPARc ligand-binding domains.15 Based on reports that TanIIA
showed anti-inflammatory, antioxidant, and antiadipogenesis
effects, we considered that TanIIA may have inhibitory effects
on the main pathogenic pathways of GO.
In this study, we investigated the effect of TanIIA on the
expression of proinflammatory genes and on adipocyte
differentiation, and its antioxidant effects, in primary cultures
of orbital fibroblasts from patients with GO.
PATIENTS AND METHODS
Reagents
The regents were purchased as follows: TanIIA (Korea Food &
Drug Administration, Osong Health Technology Administration
Complex, Cheongju, Korea); Dulbecco’s modified Eagle’s
medium (DMEM):F12 (1:1), fetal bovine serum (FBS), penicil-
lin, and gentamycin (Hyclone Laboratories, Inc., Logan, UT,
USA); 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyl-tetrazolium bro-
mide (MTT), Oil Red O, and 2 0-animo-3 0-methoxyflavone
(PD98059) (Sigma-Aldrich Corp., St. Louis, MO, USA); bromo-
deoxyuridine (5-bromo-2-deoxyuridine [BrdU]) cell prolifera-
tion assay kit (Chemicon, Temecula, CA, USA); annexin V–
FITC apoptosis kit (BD Biosciences, Franklin Lakes, NJ, USA);
recombinant human (rh) IL-1b (R&D Systems, Minneapolis,
MN, USA); anti-heme oxygenase (HO)-1, anti-phospho-extra-
cellular-regulated kinase (ERK) 1/2, anti-ERK 1/2, anti-phos-
pho-Akt, anti-phospho-phosphatidylinositol 3-kinase (PI3-K),
and anti-phospho-c-Jun N-terminal kinase (JNK) (Cell Signaling,
Danvers, MA, USA); and anti-PPARc antibody, anti-CCAAT-
enhancer-binding protein (C/EBP) a antibody, anti-C/EBP b
antibody, anti-HO1 antibody, and anti-b-actin antibody (Santa
Cruz Biotechnology, Santa Cruz, CA, USA).
Cell and Tissue Culture Protocols
Orbital adipose/connective tissue specimens were obtained in
the course of orbital decompression surgery for severe GO (n¼
6; four women and two men, aged 25–58 years). Normal orbital
adipose/connective tissue specimens were collected in the
course of orbital surgery for other noninflammatory problems
from patients with no history of thyroid disease or GO and
with no clinical evidence of GO (n¼ 4; three women and one
man, aged 31–67 years). The GO patients had not received
steroid medication for at least 3 months before surgery, and
were euthyroid at the time of surgery. The clinical activity
scores at the time of tissue harvest were below 4 in all patients.
None of the patients had been treated previously with orbital
radiotherapy. The research followed the tenets of the
Declaration of Helsinki and was approved by the institutional
review board of Severance Hospital (4-2011-05-90), Yonsei
University College of Medicine, Seoul, Korea, and all study
participants gave their written informed consent.
Orbital fibroblast cultures were established in accordance
with published methods.17 Tissue explants were minced and
placed directly in plastic culture dishes to allow preadipocyte
fibroblasts to proliferate. Cells were incubated in DMEM:F12
(1:1) containing 20% FBS, penicillin (100 U/mL), and genta-
mycin (20 lg/mL) in a humidified 5% CO2 incubator at 378C,
and maintained in two 80-mm flasks with DMEM:F12 (1:1)
containing 10% FBS and antibiotics. Monolayers were passaged
serially by gently treating with trypsin/EDTA. The strains were
stored in liquid N2 until needed and used between the first and
fifth passages. Cultured orbital fibroblasts were pretreated with
TanIIA before incubation with rh IL-1b to study the suppressive
effect of TanIIA on inflammation.
Cell Viability and Apoptosis Assays
To evaluate the effect of TanIIA on cell viability, orbital
fibroblasts were seeded into 24-well culture plates (1 3 105
cells/well) and treated with different concentrations of TanIIA
(0–30 lM) for 6 and 24 hours. After treatment, cells were
washed, incubated with 5 mg/mL MTT solution for 3 hours at
378C, then solubilized in ice-cold isopropanol and analyzed
spectrophotometrically. The absorbance of the dye was
measured at 560 nm, with background subtraction at 630
nm, with a microplate reader (EL 340 Biokinetics Reader; Bio-
Tek Instruments, Winooski, VT, USA).
To evaluate the effect of TanIIA on the apoptosis of orbital
fibroblasts, an annexin V–FITC kit was used to detect apoptotic
cells. Cells were washed with PBS and incubated in serum-free
DMEM in the presence of TanIIA at 0 to 30 lM for 6 and 24
hours. Cells were washed and incubated for 15 minutes at
room temperature in the presence of annexin V labeled with
FITC and propidium iodide (PI). In total, 10,000 cells were
excited at 488 nm, and emission was measured at 530 and 584
nm to assess FITC and PI fluorescence, respectively.
Lactate Dehydrogenase (LDH) Assay
The cytotoxicity of TanIIA in tissue culture was determined
using the LDH leakage assay. To prepare for the LDH assay,
orbital fat tissues were cultured with media containing varying
TanIIA concentrations (0–30 lM) for 6, 24, or 48 hours. The
medium was transferred to a 1.5-mL microcentrifuge tube and
centrifuged at 12,000g and 48C for 15 minutes to remove cell
debris. Then, 100 lL of each sample was added to the substrate
solution and the absorbance at 490 nm was measured using a
microplate reader (VERSAmax; Molecular Devices, Sunnyvale,
CA, USA). Activity of LDH was obtained by measuring the
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decrease in nicotinamide adenine dinucleotide absorbance
over time (slopes).
Quantitative Real-Time PCR
Total RNA (1 lg) was isolated and reverse transcribed into
complementary DNA according to the manufacturer’s instruc-
tions (#74104; Qiagen, Valencia, CA, USA). The resulting cDNA
was amplified on an ABI 7300 real-time PCR thermocycler
(Applied Biosystems, Carlsbad, CA, USA) using the TaqMan
universal PCR master mix and recommended PCR conditions to
quantitatively assess gene transcript levels in the cell samples.
All PCR reactions were performed in triplicate. The catalog
numbers (#639543; Clontech Laboratories–Takara Bio, Moun-
tain View, CA, USA) of the primers were Hs00985639_m1 for IL-
6, Hs00174103_m1 for IL-8, Hs00234140_m1 for monocyte
chemotactic protein (MCP)-1, and H299999905_ml for glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH). The GAPDH
expression was used for normalization, and the results are
expressed as fold change in the threshold cycle (Ct) value
relative to the control group using the 2DDCt method.18
Intracellular ROS Measurement
Cigarette smoke extract (CSE) was prepared in accordance
with published methods,5 using commercially available,
filtered cigarettes (Marlboro 20 class A cigarettes, made in
Korea by Philip Morris Korea, Inc. (Seoul, Korea), and
FIGURE 1. Effect of TanIIA on the viability of orbital fibroblasts. (A) Orbital fibroblasts (1 3 105) of GO patients and normal control (non-GO)
individuals were seeded in 24-well culture plates and treated with different concentrations of TanIIA (0–30 lM) for 6 and 24 hours. After treatment,
assays with MTT were performed to test for viability. (B) Orbital fibroblasts from GO patients and non-GO individuals were cultured in conditioned
media containing increasing doses (0–30 lM) of TanIIA for different treatment times (6, 24, and 48 hours). After treatment, toxicity was determined
by measuring LDH release. (C) Orbital fibroblasts of GO patients were incubated with TanIIA at 0 to 30 lM for 6 and 24 hours. An annexin V–FITC
kit was used to detect phosphatidylserine externalization, as an index of apoptosis. Percentage of stained cells with annexin V was analyzed by flow
cytometry. Results are expressed as percentage of untreated control values presented as mean 6 SD. Assays were performed in triplicate with cells
from three different donors. Primary orbital cells at passages 1 to 5 were used. Differences between treated and untreated cells are indicated (in
contrast to cells not treated with TanIIA, *P < 0.05).
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containing 8.0 mg of tar and 0.7 mg of nicotine). The
noncytotoxic doses of CSE and H2O2 were determined as
previously described,5 using the MTT assay. A dose of 2% CSE
or 200 lM H2O2 was determined to be noncytotoxic.
Release of ROS was determined with 5-(and 6)-carboxy-20,70-
dichlorodihydrofluorescein diacetate (H2DCFDA; Molecular
Probes, Inc., Eugene, OR, USA), an oxidant-sensitive fluorescent
probe, as previously described.19 The H2DCFDA is deacetylated
intracellularly by esterase, forming H2DCF, which is oxidized by
ROS to 20,70-dichlorofluorescein (DCF), a highly fluorescent
compound. Orbital fibroblasts were seeded on glass-bottomed
60-mm2 dishes overnight and pretreated with TanIIA (0–10 lM)
for 24 hours in the presence or absence of 2% CSE or 200 lM
H2O2 as described above for 1 hour. Cells were then incubated
with 10 lM H2DCFDA (Invitrogen, Eugene, OR, USA) in growth
medium for 30 minutes at 378C. Cells were washed with PBS,
and analyzed with a flow cytometer (ELITE flow cytometer;
Coulter Cytometry, Inc., Hialeah, FL, USA).
Adipogenesis
Orbital fibroblasts were exposed to a differentiation protocol
according to our previous reports5,17 to enhance adipogenesis.
The cells were grown to confluence in six-well plates, and then
exposed to differentiation medium for 10 days. The culture
medium was changed to serum-free DMEM-glucose supple-
mented with 33 lM biotin, 17 lM pantothenic acid, 10 lg/mL
transferrin, 0.2 nM T3, 1 lM insulin (Boehringer-Mannheim,
Manheim, Germany), 0.2 lM carbaprostaglandin (cPGI2;
Calbiochem, La Jolla, CA, USA), and a PPARc agonist,
rosiglitazone 10 lM (Cayman, Ann Arbor, MI, USA). For the
first 4 days, 1 lM insulin, 10 lM dexamethasone, 0.1 mM
isobutylmethylxanthine (IBMX) and differentiation media was
used and after the first 4 days, dexamethasone and IBMX were
excluded from the media. Rosiglitazone 10 lM was added from
day 1 for further stimulation of adipogenesis. The differentia-
tion protocol was continued for 10 days, during which the
medium was replaced every 2 to 3 days. To evaluate the effect
of TanIIA on adipocyte differentiation, we exposed cultures to
TanIIA (0, 1, 5, 10 lM) for the entire 10-day differentiation
period.
Oil Red O Staining
Cells were stained with Oil Red O as described by Green and
Kehinde.20 A 0.5% Oil Red O stock solution was prepared and
passed through a 0.2-lm filter. To prepare the working
solution, 6 mL stock solution was mixed with 4 mL distilled
water, left for 1 hour at room temperature, and filtered through
a 0.2-lm filter. Cells were washed twice with 13 PBS, fixed
with 10% formalin in PBS for 1 hour at 48C, and stained with
300 lL Oil Red O working solution for 1 hour at room
temperature. The dishes were washed with distilled water
before being visualized using an Axiovert (Carl Zeiss, Jena,
Germany) light microscope and photographed at 340 and
3100 using an Olympus BX60 light microscope (Olympus,
Melville, NY, USA).
To measure lipid accumulation, cell-bound Oil Red O was
solubilized with 100% isopropanol, and the optical density of
the solution was measured with a spectrophotometer at 490
nm. Experiments for the quantitative assessment of adipogenic
differentiation were performed in triplicate in cells from
different donors, and the results were normalized to the
absorbance of untreated control differentiated cells.
Western Blot Assay
Differentiated cells were washed with ice-cold PBS and lysed
with cell lysis buffer (20 mM HEPES [pH 7.2], 10% [vol/vol]
glycerol, 10 mM Na3VO4, 50 mM NaF, 1 mM phenylmethylsul-
fonyl fluoride, 0.1 mM dithiothreitol, 1 lg/mL leupeptin, 1 lg/
mL pepstatin, and 1% [vol/vol] Triton X-100; Sigma-Aldrich
Corp.) on ice for 30 minutes. Lysates were centrifuged for 10
minutes at 12,000g and the cell homogenate fractions stored at
708C before use.
Protein concentrations in the supernatant fractions were
determined by the Bradford assay. Equal amounts of protein
(50 lg) were boiled in sample buffer and resolved by 10% (wt/
vol) SDS-PAGE. Proteins were transferred to polyvinylidene
fluoride membranes (Immobilon; Millipore, Billerica, MA,
USA), probed overnight with primary antibodies in Tris-
buffered saline containing Tween 20 (TBST), and washed
three times with TBST. Immunoreactive bands were detected
with horseradish peroxidase–conjugated secondary antibody
and developed using an enhanced chemiluminescence kit
(Amersham Pharmacia Biotech, Piscataway, NJ, USA) and
exposed to X-ray film (Amersham Pharmacia Biotech).
FIGURE 2. Effect of TanIIA on tissue mRNA transcript levels of IL-6, IL-
8, and MCP-1. After the treatment of tissue cultures with various
concentrations of TanIIA for 6 hours, total RNA (1 lg) was isolated and
reverse transcribed into cDNA, which was amplified for IL-6, IL-8, and
MCP-1 mRNA by real-time PCR. Gene transcript levels of IL-6 (A), IL-8
(B), and MCP-1 (C) are shown as mean 6 SD fold depression in
cytokine mRNA levels relative to control samples without TanIIA
treatment. Experiments were performed in triplicate with cells from
three different donors. Primary orbital cells at passages 1 to 5 were
used. Differences between treated and untreated cells are indicated (in
contrast to cells not treated with TanIIA, *P < 0.05). NL, normal
control.
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Statistical Analysis
All values are expressed as the mean 6 SD of three separate
experiments, using cells from three different individuals.
Statistical analysis was performed with repeated measures
ANOVA and independent t-test with Bonferroni test as a post
hoc test to identify differences between control and drug-
treated samples using the SPSS program for Windows, version
20.0 (SPSS, Inc., Chicago, IL, USA). A P value less than 0.05 was
considered significant.
RESULTS
Effect of TanIIA on the Viability of Orbital
Fibroblasts
To determine the nontoxic concentrations of TanIIA in orbital
fibroblasts, the MTT assay, LDH cytotoxicity assay, and
annexin V-FITC apoptosis assay were performed. Exposure
of cells to 10 lM or less of TanIIA for 6 and 24 hours did not
decrease cell viability below 95% in both normal and GO
orbital fibroblasts (Fig. 1A). Release of LDH from cells treated
with TanIIA (0–30 lM) for 6, 24, and 48 hours did not
decrease cell viability in both normal and GO orbital
fibroblasts (Fig. 1B). Exposure of cells to 10 lM or less of
TanIIA for both 6 and 24 hours did not induce a significant
level of apoptosis or necrosis in GO orbital fibroblasts (Fig.
1C). Therefore, noncytotoxic concentrations (0–10 lM) of
TanIIA were used to study the therapeutic effect of TanIIA in
Graves’ orbital fibroblasts in this study.
Effect of TanIIA on the Expression of mRNA of IL-
1b-Induced Proinflammatory Cytokines
We investigated the effects of increasing treatment doses of
TanIIA on IL-6, IL-8, and MCP-1 mRNA expression in response
to IL-1b (10 lg/mL, 16 hours) challenge of orbital fibroblasts
from GO and normal orbital fibroblasts. The 16-hour time point
was chosen based on previous dose-response and time-course
studies that indicated upregulation of IL-6, IL-8, and MCP-
1,17,21,22 and also confirmed by data from our experiments
(Supplementary Fig. S1). Pretreatment with 5 lM TanIIA for 6
hours resulted in a significant inhibition of IL-6, IL-8, and MCP-1
mRNA expression induced by IL-1b in both normal and GO
orbital fibroblasts (P < 0.05, Fig. 2).
TanIIA Treatment Reduced CSE- and H2O2-
Stimulated ROS Production in GO Orbital
Fibroblasts
Reactive oxygen species production detected by a ROS-
sensitive fluorescent probe, DCFDA in GO orbital fibroblasts
stimulated with either 2% CSE or 200 lM H2O2 for 1 hour was
FIGURE 3. Tanshinone IIA decreases ROS levels in orbital fibroblasts from GO. Orbital fibroblasts were incubated with 10 lM H2DCFDA for 30
minutes in various concentrations of TanIIA (0–10 lM) in the presence or absence of 2% CSE (A, B) or 200 lM H2O2 (C, D) for 1 hour, and the
fluorescence intensities were analyzed using FACS. Results are expressed as percentage of untreated control values presented as mean 6 SD (A, C).
Flow cytometry plots are presented (B, D). Assays were performed in triplicate with cells from three different GO donors. Primary orbital cells at
passages 1 to 5 were used. Differences between treated and untreated cells are indicated (in contrast to cells not treated with TanIIA, *P < 0.001).
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significantly suppressed by TanIIA pretreatment in a dose-
dependent manner (all P < 0.001; Fig. 3).
Effect of TanIIA on HO-1 Expression in Orbital
Fibroblasts
Because the production of HO-1, an antioxidant enzyme, may
lead to changes in intracellular redox status, we investigated
whether TanIIA induces HO-1 expression in orbital fibroblasts.
The expression of the HO-1 protein was significantly upregu-
lated on treatment with TanIIA (1–10 lM) for 24 hours in a
dose-dependent manner in both GO (Fig. 4A) and normal
orbital fibroblasts (Fig. 4B). In GO orbital fibroblasts, the
amount of HO-1 protein production by TanIIA was stronger
than that in normal orbital fibroblasts (P ¼ 0.004). Orbital
fibroblasts were also treated with various concentrations of
TanIIA (0–10 lM) and various time conditions (6–48 hours)
and showed a dose-dependent effect on HO-1 protein
expression in GO orbital fibroblasts (Fig. 4C).
Signaling Pathways of TanIIA-Induced HO-1
Expression in Orbital Fibroblasts
To investigate the molecular mechanism of HO-1 induction by
TanIIA in orbital fibroblasts, we observed the effect of TanIIA
on ERK1/2, Akt, PI3-K, and JNK activation. The data in Figures
5A and 5B show that 10 lM TanIIA provoked a rapid and
relevant activation of ERK1/2, whose phosphorylation was
maximal at 30 minutes in GO cells and at 15 minutes in non-
GO cells, and declined to basal levels at 180 minutes; PI3-K
phosphorylation was suppressed by TanIIA treatment in both
GO and non-GO cells; JNK phosphorylation was enhanced
only in non-GO cells with a time-course similar to that
observed for EKR1/2; the phosphorylation of Akt was
enhanced at the 5-minute challenge in GO cells.
Thus, ERK1/2 was identified as a target of TanIIA, with its
phosphorylation being strongly enhanced at 15- to 30-minute
challenge. To elucidate the upstream signaling events leading
to the induction of HO-1 expression in TanIIA-treated orbital
fibroblasts, different kinase inhibitors were used, including
PD98059 (ERK inhibitor), SB203580 (p38 MAPK inhibitor),
SP600125 (JNK inhibitor), LY294002 (PI3-K inhibitor), and
U0126 (MAPK inhibitor). The PD98059 significantly blocked
phosphorylation of ERK 1/2 in GO orbital fibroblasts pretreat-
ed with 10 lM TanIIA for 16 hours (P < 0.001; Fig. 5C). When
cells were pretreated with PD98059, TanIIA-induced HO-1 was
also significantly inhibited (P < 0.001; Fig. 5D), suggesting that
activation of the ERK signaling pathway was required for the
TanIIA induction of HO-1 protein expression in orbital
fibroblasts.
FIGURE 4. Dose-dependent effect of TanIIA in HO-1 expression in orbital fibroblasts. After incubating orbital fibroblasts with various concentrations
of TanIIA (0–10 lM) for 24 hours and subsequently washing them twice with PBS, cell lysates were electrophoresed and probed by Western blot
with HO-1– and b-actin–specific antibodies. Data were normalized to the b-actin level, and the relative densities were quantified with a
densitometer. Results are representative of three separate experiments of GO (A) and normal control (B) patients (in contrast to cells not treated
with TanIIA, *P < 0.001). (C) After incubating orbital fibroblasts from GO with various concentrations of TanIIA (0–10 lM) and various time
conditions (6–48 hours) and then washing twice with PBS, cell lysates were electrophoresed and probed by Western blot with HO-1– and b-actin–
specific antibodies (in contrast to cells not treated with TanIIA, *P < 0.05). Triplicate measurements from three different donors were averaged, and
data are expressed as mean 6 SD. Primary orbital cells at passages 1 to 5 were used.
Tanshinone IIA in Graves’ Orbitopathy IOVS j September 2014 j Vol. 55 j No. 9 j 5905
Effect of TanIIA on Adipogenesis in Orbital
Fibroblasts
To examine whether TanIIA had any suppressive effects on
adipogenesis, it was added at day 1 into adipogenic medium,
including rosiglitazone, and continued for the 10-day differen-
tiation period, being replaced whenever media was replaced.
High-power (3200,3400) microscopic examination of Oil Red
O staining showed that TanIIA dose-dependently decreased the
size and number of intracytoplasmic lipid droplets in cells
treated with or without rosiglitazone (Fig. 6A). Preadipocyte
fibroblasts that did not convert into adipocytes were uniform
in size and stellate in shape, which maintained viable
fibroblastic morphology. To quantitatively evaluate adipocyte
differentiation, the optical density of stained cell lysates was
measured and TanIIA-treated cells showed significantly de-
creased absorbance at 490 nm in a dose-dependent manner (P
< 0.01; Fig. 6B).
Western blot analysis was performed to investigate the
effect of TanIIA on the expression of the adipogenic
FIGURE 5. Signaling pathways of TanIIA-induced HO-1 expression in orbital fibroblasts. (A) Effects of TanIIA on ERK 1/2, Akt, PI3-K, and JNK
phosphorylation in orbital fibroblasts of GO. Cells were treated with TanIIA (10 lM) for various time periods and lysed. Cell lysates were
electrophoresed and probed by Western blot with phospho-ERK 1/2, ERK 1/2, phospho-Akt, phospho-PI3-K, phospho-JNK, and b-actin-specific
antibodies. Equal loading in each lane was demonstrated by the similar intensities of b-actin. Quantification by densitometry, normalized to the b-
actin level in the same sample, is shown for phospho-ERK 1/2, phospho-Akt, phospho-PI3-K, and phospho-JNK. (B) Effects of TanIIA on ERK 1/2,
Akt, PI3-K, and JNK phosphorylation in orbital fibroblasts of normal controls. A specific ERK kinase inhibitor, PD98059, significantly blocked the
phosphorylation of ERK 1/2 in GO orbital fibroblasts pretreated with 10 lM TanIIA for 16 hours. (C) When cells were pretreated with PD98059,
TanIIA-induced HO-1 was also significantly inhibited. The data in the column are the mean relative density ratios 6 SD. Experiments were
performed in triplicate with cells from three different donors. Primary orbital cells at passages 1 to 5 were used. *P < 0.001 versus untreated control
differentiated cells.
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transcription regulators PPARc, C/EBP a, and C/EBP b. The
protein levels of PPARc and C/EBPa were significantly
attenuated when treated with 5 to 10 lM TanIIA (P < 0.01;
Fig. 7A).
When intracellular ROS levels were measured on days 0, 1,
4, 7, and 10 of adipocyte differentiation in GO orbital
fibroblasts, the ROS levels were all significantly lower in
differentiating cells treated with 10 lM TanIIA on days 4, 7, and
10 compared with cells without TanIIA treatment (all P < 0.01;
Fig. 7B).
DISCUSSION
In this study, we investigated the therapeutic efficacy and the
related molecular mechanisms of TanIIA in the pathogenesis of
GO in orbital fibroblasts. We found that TanIIA exhibited
significant suppressive effects on inflammation, oxidative
stress, and adipogenesis, all of which were the major
pathologic mechanisms associated with the development of
GO.
Tanshinone IIA, a lipophilic diterpene, has been reported to
show unique biological properties that include anti-inflamma-
tory,11–13 antioxidant,23–25 and antiadipogenic15,16 activities. In
the present investigation, we observed that TanIIA inhibited
the IL-1b induction of the mRNA expression of proinflamma-
tory cytokines in a dose-dependent manner. Tanshinone IIA has
been reported to decrease the production of proinflammatory
cytokines (TNF-a, IL-1b, IL-6, and MCP-1) by neutrophils,
astrocytes, and macrophages.26,27 Different mechanisms are
involved in the anti-inflammatory action of TanIIA in many cell
systems, as it targets multiple intracellular signaling pathways
such as nuclear factor-jB activation and MAPK family
phosphorylation.13,26–28
There is evidence that oxidative stress plays an important
role in the pathogenesis of GO.29–31 Superoxide radicals
stimulate orbital fibroblasts to proliferate and to produce
glycosaminoglycan32 and H2O2 induces the expression of HLA-
FIGURE 6. Effect of TanIIA on adipogenesis in GO orbital fibroblasts. (A) Microscopic examination of Oil Red O–stained cultures exposed to TanIIA
in the adipogenesis of GO orbital fibroblasts. TanIIA treatment on the first day of initiation of 10-day adipogenesis in adipogenic media not
containing rosiglitazone, or rosiglitazone and various concentrations (0–10 lM) of TanIIA. Cells at passages 1 to 5 were used. Cells were fixed with
10% formalin for 1 hour and then stained with Oil Red O to measure lipid accumulation and examined microscopically (340,3100,3200,3400). (B)
Cell-bound Oil Red O was solubilized with 100% isopropanol and the optical density of the solution was measured at 490 nm to obtain a quantitative
assessment of adipogenesis. Experiments for the quantitative assessment of adipogenic differentiation were performed in triplicate in cells from
three different donors, and the results were normalized to the absorbance of untreated control differentiated cells. Primary orbital cells at passages 1
to 5 were used. Results are expressed as percentage of untreated control values, presented as mean 6 SD (in contrast to cells not treated with
TanIIA, *P < 0.01, **P < 0.001).
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DR and heat shock protein 72.33 Smoking is the strongest
known environmental factor stimulating the occurrence and
aggravation of GO by enhancing the generation of ROS and
reducing antioxidant production.34 In our study, TanIIA
significantly inhibited CSE or H2O2-induced ROS generation
in a dose-dependent manner in orbital fibroblasts from GO.
Tanshinone IIA is reported to be a natural antioxidant and is
known to protect various kinds of cells. Previous studies in
vitro have revealed the antioxidant action of TanIIA by
attenuating intracellular ROS levels in neonatal rat cardiomy-
ocytes.35,36 In another study, TanIIA protected H9c2 cells via
preserving mitochondrial function by reducing the excess
production of mitochondrial superoxide, superoxide dismu-
tase activity, intracellular nitric oxide, and calcium levels, and
restoring cellular ATP contents.37 In brain microvascular
endothelial cells, TanIIA suppressed the expression of vascular
cell adhesion molecule-1 and intercellular adhesion molecule-1
by suppressing ROS production.38
To gain further insight into the mechanism of TanIIA on
ROS reduction, we next examined the effect of TanIIA on the
expression of HO-1, an important cytoprotective, anti-inflam-
matory, and antioxidant enzyme. The key enzyme in heme
catabolism, HO-1 functions as a cytoprotective mechanism
against inflammatory responses and ROS insults through the
anti-inflammatory action of its metabolite, CO, and the
antioxidant activities of another metabolite, bilirubin.39 The
induction of HO-1 is considered part of the generalized
protective response to oxidative stress, as an active defense
mechanism. Our data showed that TanIIA had a profound
inductive effect on HO-1 protein expression in human orbital
fibroblasts, especially in GO cells. To identify which signal
cascade controlled the activation of HO-1 by TanIIA, we
examined the effects of MAPK and PI3-K inhibitors on the
TanIIA-mediated upregulation of HO-1 expression; the results
suggest that TanIIA-induced HO-1 expression is dependent on
the activation of ERK rather than JNK 1/2, p38 MAPK, and PI3-
K. The blockade of the ERK pathway by PD98059 strongly
attenuated the increase of HO-1 by TanIIA, implying the
involvement of the ERK signaling pathway in this antioxidant
action. In our cells from GO, the induction of HO-1 expression
FIGURE 7. Effect of TanIIA on the expression of adipogenic transcriptional regulators in GO orbital fibroblasts and intracellular ROS in
differentiating orbital fibroblasts during adipogenesis. (A) Tanshinone IIA (5–10 lM) treatment for the entire 10-day differentiation period in
adipogenic media. After 10 days, cell lysates were subjected to Western blot analysis of PPARc, C/EBP a, and C/EBP b protein expression.
Quantification by densitometry, normalized to the b-actin level in the same sample, is shown for PPARc and C/EBP a. The data in the column are the
mean relative density ratios 6 SD. (B) Confluent fibroblasts from GO patients were subjected to a differentiation protocol that included adipogenic
supplements for 10 days. To determine the suppressive effect of TanIIA on adipogenesis, 10 lM TanIIA was also added during the entire 10-day
differentiation period. Reactive oxygen species were measured by flow cytometry H2DCFDA on days 0, 1, 4, 7, and 10 of adipogenesis. The results
are expressed as percentages of the untreated control values, and presented as means 6 SD. The assays were performed at least three times with
cells from three different GO donors. Primary orbital cells at passages 1 to 5 were used. Differences between treated and untreated cells are
indicated (in contrast to cells not treated with TanIIA, *P < 0.01).
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occurred together with ROS reduction. This is consistent with
the finding that induction of HO-1 by isorhamnetin, a 30-O-
methylated metabolite of quercetin,40 flavonoid kaempferol,41
and curcumin, an anti-inflammatory agent extracted from
Curcuma longae,42 leads to a reduction in ROS production in
RAW 264.7 cells. Curcumin also was found to reduce ROS
levels by upregulating HO-1 expression in human retinal
pigment epithelial cells.43 TanIIA might cause ROS reduction
by upregulating HO-1 protein in GO orbital fibroblasts;
however, we have not yet proved the causal relationship,
which would be investigated in our future study.
Tanshinone IIA significantly inhibited adipogenesis through
induction of apoptosis in 3T3-L1 preadipocytes and adipo-
cytes.15,44 Tanshinone IIA also was found to decrease the
amount of intracellular triglycerides and glycerol-3-phosphate
dehydrogenase activity in 3T3-L1 adipocytes.44 Furthermore,
TanIIA inhibits 3T3-L1 preadipocyte differentiation and the
transcriptional activity of full-length PPARc and PPARc ligand-
binding domains.15 The effects of TanIIA are mediated through
its property as a natural antagonist of PPARc.15 We have
previously reported that adipogenesis in Graves’ orbital
fibroblasts was upregulated by the oxidants H2O2 and CSE,
and that this was suppressed in a dose-dependent manner by
an antioxidant, quercetin, in parallel with a reduction in ROS.5
In our study, microscopic results with Oil Red O staining with
quantification showed that TanIIA suppressed adipocyte
differentiation in a dose-dependent manner, and also sup-
pressed the expression of PPARc and C/EBPa protein.
Tanshinone IIA also suppressed ROS generation in differenti-
ating orbital fibroblasts during adipogenesis. Together, these
suggest that TanIIA may suppress adipogenesis through its
antioxidant effects.
Overall, our findings suggest that Tan IIA has the potential
for anti-inflammatory, antioxidant, and antiadipogenic therapy
in orbital fibroblasts from GO. Although TanIIA shows
promising results in many studies, these have the limitation
of being in vitro studies. As the oral bioavailability of TanIIA is
very low,45 it has limitations with respect to use in patients.
However, recent studies have shown that solid dispersions of
TanIIA with silica nanoparticles or low-molecular-weight
chitosan achieved complete dissolution, increased the absorp-
tion rate, maintained drug stability, and showed improved oral
bioavailability compared with TanIIA alone.37,45 A study
protocol for a randomized controlled trial has also been
released to investigate the effect of sodium tanIIA sulfate and
simvastatin on elevated serum levels of inflammatory markers
in patients with coronary heart disease.46 We believe the
results in this study are noteworthy, as TanIIA can be used for
the treatment of GO; further studies in humans using more
developed types of TanIIA are needed to confirm these results.
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